VIVO Cannabis and Trulieve Posted Strong Performance Last Week


Feb. 4 2019, Updated 8:14 a.m. ET

Cannabis sector performance

Last week cannabis stocks performed well due to strength in the broader equity market with the S&P 500 Index rising by 1.6%. From January 25 to February 1, the Horizons Marijuana Life Sciences Index ETF (HMMJ), which tracks the North American Medical Marijuana Index, returned 11.4%, while the ETFMG Alternative Harvest ETF (MJ) returned 12.1%.

Article continues below advertisement

Stock performance

Of the nine cannabis stocks considered for our analysis, seven companies delivered positive returns, while two companies were in negative territory.

Last week, VIVO Cannabis (VVCIF), Trulieve Cannabis (TCNNF), Curaleaf Holdings (CURLF), and iAnthus Capital Holdings (ITHUF) posted strong performances with double-digit rises. The stock price of VIVO Cannabis increased by 37.1%, while Trulieve, Curaleaf, and iAnthus returned 20.5%, 18.2%, and 10.2%, respectively.

Last week, Curaleaf expanded its leadership team with the appointment of Neil Davidson as CFO and Todd Goffman as general counsel and secretary. The company also appointed Peter Clatemanhas as its executive vice president of business development and Jonathan Faucher as the executive vice president of finance.

During the same period, Planet 13 Holdings (PLNHF), Wayland Group (MRRCF), and Acreage Holdings (ACRGF) have returned 9.5%, 5.8%, and 4.1%, respectively.

Stock in negative territory

Last week, the stock prices of MedMen Enterprises (MMNFF) and The Green Organic Dutchman Holdings (TGODF) fell by 2.9% and 0.9%, respectively. On January 29, MedMen’s former CFO, James Parker, filed a suit against MedMen Enterprises in the Superior Court of California in Los Angeles County, alleging breach of contract and wrongful termination. Parker had resigned in November of 2018.


More From Market Realist

  • COVID-19 vaccine and Vaxart logo
    Hate Injections? Vaxart Stock Might Be Attractive After the Crash
  • COVID-19 virus and Cocrystal Pharma logo
    Cocrystal Pharma Stock Is a Speculative Play on COVID-19 Drug
  • Stethoscope and a smartphone
    Why Bionovate Technologies (BIIO) Stock Is a Risky Bet in 2021
  • Precipio Biotech
    Is Precipio (PRPO) a Good Stock to Buy? A Look at the Year Ahead
  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.